Product

Ambrisentan + Sotagliflozin

1 clinical trial

1 indication

Indication

Type 1 Diabetes Mellitus With Diabetic Nephropathy

Clinical trial

Individual and Combined Endothelin Receptor and SGLT1/2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial

Status: Not yet recruiting, Estimated PCD: 2025-03-01